Pulmonology · Interstitial Lung Disease Due to Surfactant Protein C (SP-C) Deficiency

Treatment and Daily Management: Supporting Your Lung Health

At a Glance

Management of SP-C deficiency-related interstitial lung disease is individualized because no treatment repairs the underlying genetic change. Oxygen, nutrition, infection prevention, selected medicines, lung monitoring, and early transplant evaluation support care when disease progresses.

Managing surfactant protein C (SP-C) deficiency requires a shift in perspective: because there is no “cure” that fixes the genetic mutation itself, the goal of treatment is to protect the lungs, support growth, and manage symptoms ^[1]^[2].

Care is highly individualized because two people with the exact same mutation can have vastly different needs ^[3]. Your medical team will likely focus on a “treatable traits” approach—addressing specific issues like low oxygen, poor growth, or lung inflammation as they arise ^[4].

The Foundation: Supportive Care

Supportive care is the most critical part of daily management, especially for infants and growing children. It provides the body with the resources it needs to handle the extra “work” of breathing.

Oxygen Therapy: Many patients require supplemental oxygen to maintain healthy levels in the blood. This may be needed only during sleep or exercise, or it may be required 24/7 ^[5]^[1]. Safety Rule: Oxygen flow and target saturations must be individually prescribed. Do not increase or decrease flow outside a written plan. Keep oxygen strictly away from smoking, vaping, flames, and heat sources.
Nutritional Support: Breathing with stiff lungs burns a significant amount of energy. Many children require high-calorie diets or even feeding tubes (G-tubes) to ensure they continue to grow and gain weight, which is essential for lung development ^[1]^[6].
Infection Prevention: Because a simple cold can lead to a severe lung flare-up, work with your care team on an individualized immunization and RSV-prevention plan (as RSV prevention depends on age, pregnancy, and risk status) ^[6]^[7]. Hand hygiene and smoke avoidance are also key.
Pulmonary Rehabilitation: For older children and adults, structured exercise programs can help improve stamina and reduce the sensation of breathlessness ^[8]^[5].

Off-Label Medications

There are currently no FDA-approved disease-modifying drugs specifically for SFTPC mutations. Doctors sometimes trial medications “off-label,” meaning they were originally approved for other conditions but may help reduce lung inflammation in some patients.

Medication	Purpose	Monitoring & Safety
Hydroxychloroquine (HCQ)	Trialed with the aim to reduce inflammation, though evidence is limited ^[9].	Eye Exams: Requires regular checks with an ophthalmologist to monitor for retinal damage, based on dose and risk ^[10]. Heart: May require an ECG to monitor the heart’s electrical rhythm (QT interval) ^[11].
Corticosteroids	Used to dampen severe inflammation during a period of worsening symptoms ^[12].	Long-term Risks: Prolonged use can lead to weight gain, bone thinning, and increased infection risk. Never stop abruptly. ^[13].
Azithromycin	Though an antibiotic, it is sometimes trialed for anti-inflammatory properties ^[14].	Hearing & Heart: Long-term use requires monitoring for heart rhythm issues (QT risk), especially if combined with HCQ ^[11].

A Note on Effectiveness: A recent clinical trial found that hydroxychloroquine did not show a clear benefit for everyone with childhood lung disease ^[15]. Because responses are so variable and evidence is limited, your doctor should set clear “goals” for these medications (like improving oxygen levels) and stop them if those goals aren’t met ^[4]. Never start, stop, or change doses independently.

Monitoring for Progression

Your care team will use several tools to track whether the disease is stable or advancing:

Pulmonary Function Tests (PFTs): These measure how much air the lungs can hold and how fast it can be blown out. A decline, such as 10% or more in the FVC (Forced Vital Capacity), is often a sign clinicians use to monitor progression, though this must be interpreted over time and with age ^[16]^[17].
Six-Minute Walk Test: This measures how far you can walk and how your oxygen levels react to physical activity ^[18]^[19].
Echocardiograms: These are used to screen for pulmonary hypertension (high blood pressure in the lung arteries), a serious complication that can occur if the lung disease is advanced ^[20]^[21].

When to Consider Lung Transplantation

If medications and oxygen are no longer enough to maintain a good quality of life, or if there is a steady decline in lung function, a lung transplant may be considered ^[2].

Transplant referral is usually recommended early—before a crisis occurs. Indicators for referral include a significant drop in PFT scores, the development of pulmonary hypertension, or a continuous and increasing need for high-flow oxygen ^[22]^[23]. There is no single universal cutoff for referral. While a transplant is a major surgery with its own long-term challenges, it has been a life-saving option for many infants and adults with SFTPC mutations ^[24]^[25].

Common questions in this guide

Can SP-C deficiency-related interstitial lung disease be cured?

There is currently no treatment that repairs the underlying genetic change, so care focuses on protecting lung function and supporting the person's needs. Oxygen, nutrition, infection prevention, medicines for selected problems, regular monitoring, and sometimes lung transplantation may be used.

When is oxygen needed for SP-C deficiency?

Supplemental oxygen may be needed during sleep, exercise, or all day, depending on oxygen levels and symptoms. A clinician must prescribe the flow rate and target level; do not change it without a written plan, and keep oxygen away from smoking, vaping, flames, and heat.

What medicines might be tried for SFTPC mutations?

No FDA-approved disease-modifying medicine is specifically approved for SFTPC mutations. Doctors may trial hydroxychloroquine, corticosteroids, or azithromycin off-label to address lung inflammation, but benefits vary and each medicine needs safety monitoring; never start, stop, or change one without the care team.

How can nutrition help a child with SP-C deficiency?

Breathing with stiff or diseased lungs can use extra energy, making it harder to gain weight. A care team may recommend calorie-rich nutrition or a feeding tube to support growth, which is important for lung development.

How do doctors monitor whether SP-C-related lung disease is getting worse?

Pulmonary function tests track how much air the lungs hold and how quickly it can be exhaled, while a six-minute walk test shows exercise capacity and the oxygen response to activity. Echocardiograms can screen for pulmonary hypertension, and changes are interpreted over time rather than from one result alone.

When should someone with SP-C deficiency be referred for a lung transplant?

Referral may be considered before a crisis when lung function steadily declines, pulmonary hypertension develops, or oxygen needs continue to rise despite treatment. There is no single cutoff, and early discussion with a transplant team helps determine timing based on the individual's health and quality of life.

How can families reduce infection risks with SP-C deficiency?

Families should follow an individualized immunization and RSV-prevention plan, practice careful hand hygiene, and avoid smoke and vaping exposure. The care team should tailor RSV prevention to age, pregnancy, and risk status.

Get notified when new evidence is published on Interstitial lung disease due to SP-C deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (25)

1
Clinical and genetic spectrum of interstitial lung disease in Chinese children associated with surfactant protein C mutations.
Hong D, Dai D, Liu J, et al.
Italian journal of pediatrics 2019; (45(1)):117 doi:10.1186/s13052-019-0710-2.
PMID: 31462320
2
An update to the classification, evaluation, and management of childhood interstitial lung disease in infancy: an official American Thoracic Society Clinical Practice Guideline.
McGraw MD, DeBoer E, Weinman JP, et al.
American journal of respiratory and critical care medicine 2026; (212(10)):2308-2337 doi:10.1093/ajrccm/aamag375.
PMID: 42496593
3
Surfactant Protein C-associated interstitial lung disease; three different phenotypes of the same SFTPC mutation.
Salerno T, Peca D, Menchini L, et al.
Italian journal of pediatrics 2016; (42()):23 doi:10.1186/s13052-016-0235-x.
PMID: 26925580
4
Treatable Traits in Pediatric Interstitial Lung Diseases: Bridging the Gap to Tailored Therapeutics.
Parisi GF, Papale M, Pecora G, et al.
Journal of clinical medicine 2025; (14(22)) doi:10.3390/jcm14228190.
PMID: 41303225
5
Oxygen for interstitial lung diseases.
Khor YH, Smith DJF, Johannson KA, Renzoni E
Current opinion in pulmonary medicine 2020; (26(5)):464-469 doi:10.1097/MCP.0000000000000691.
PMID: 32657832
6
[Chronic interstitial lung disease in children: Diagnostic approach and management].
Fuger M, Clair MP, El Ayoun Ibrahim N, et al.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2016; (23(5)):525-31.
PMID: 27021883
7
Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial.
Griese M, Köhler M, Witt S, et al.
Trials 2020; (21(1)):307 doi:10.1186/s13063-020-4188-4.
PMID: 32245508
8
Interstitial Lung Disease: A Review.
Maher TM
JAMA 2024; (331(19)):1655-1665 doi:10.1001/jama.2024.3669.
PMID: 38648021
9
Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients.
Kröner C, Reu S, Teusch V, et al.
The European respiratory journal 2015; (46(1)):197-206 doi:10.1183/09031936.00129414.
PMID: 25657025
10
Hydroxychloroquine retinopathy.
Yusuf IH, Sharma S, Luqmani R, Downes SM
Eye (London, England) 2017; (31(6)):828-845 doi:10.1038/eye.2016.298.
PMID: 28282061
11
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
Doyno C, Sobieraj DM, Baker WL
Clinical toxicology (Philadelphia, Pa.) 2021; (59(1)):12-23 doi:10.1080/15563650.2020.1817479.
PMID: 32960100
12
Congenital Surfactant C Deficiency with Pulmonary Hypertension-A Case Report.
Chua WC, Chen IC, Liu YC, et al.
Children (Basel, Switzerland) 2022; (9(10)) doi:10.3390/children9101435.
PMID: 36291368
13
Severe Neonatal Interstitial Lung Disease Caused by a Rare Surfactant Protein C Mutation.
Terpe F, Schwerk N, Griese M, et al.
Pediatrics 2023; (151(6)) doi:10.1542/peds.2022-060038.
PMID: 37232099
14
Clinical characteristics of SFTPC gene mutations in children: a single-center experience.
Yang T, Zhang F, Zheng G, et al.
Italian journal of pediatrics 2025; (51(1)):266 doi:10.1186/s13052-025-02101-9.
PMID: 40890883
15
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.
Griese M, Kappler M, Stehling F, et al.
Orphanet journal of rare diseases 2022; (17(1)):289 doi:10.1186/s13023-022-02399-2.
PMID: 35871071
16
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Pugashetti JV, Adegunsoye A, Wu Z, et al.
American journal of respiratory and critical care medicine 2023; (207(1)):69-76 doi:10.1164/rccm.202201-0124OC.
PMID: 35943866
17
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis.
Newton CA, Thenappan A, Liu GY, et al.
American journal of respiratory and critical care medicine 2025; (211(10)):1867-1875 doi:10.1164/rccm.202501-0317OC.
PMID: 40530983
18
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
Deterding R, Griese M, Deutsch G, et al.
ERJ open research 2021; (7(2)) doi:10.1183/23120541.00805-2020.
PMID: 34164554
19
Advanced interstitial lung disease: Evidence-based management and clinical approach.
Kattih Z, Greenstein Z, Makkar P, Gupta R
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2025; (42(2)):16206 doi:10.36141/svdld.v42i2.16206.
PMID: 40699491
20
Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.
Rahaghi FF, Kolaitis NA, Adegunsoye A, et al.
Chest 2022; (162(1)):145-155 doi:10.1016/j.chest.2022.02.012.
PMID: 35176276
21
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al.
The New England journal of medicine 2021; (384(4)):325-334 doi:10.1056/NEJMoa2008470.
PMID: 33440084
22
Referral rates and barriers to lung transplantation based on pulmonary function criteria in interstitial lung diseases: a retrospective cohort study.
Deri O, Ovadia D, Huszti E, et al.
Therapeutic advances in respiratory disease 2024; (18()):17534666231221750 doi:10.1177/17534666231221750.
PMID: 38179653
23
Pulmonary Hypertension-Related Interstitial Lung Disease: An Expert Opinion with a Real-World Approach.
Criner RN, Naranjo M, D'Alonzo G, Weaver S
Biomedicines 2025; (13(4)) doi:10.3390/biomedicines13040808.
PMID: 40299367
24
Outcome of lung transplantation for adults with interstitial lung disease associated with genetic disorders of the surfactant system.
Bermudez J, Nathan N, Coiffard B, et al.
ERJ open research 2023; (9(6)) doi:10.1183/23120541.00240-2023.
PMID: 38020562
25
Interstitial lung disease as an indication for pediatric lung transplant.
Kuklinski CA, Blatter JA
Pediatric pulmonology 2024; (59(9)):2313-2320 doi:10.1002/ppul.26812.
PMID: 38131509

This page is for informational purposes only and does not constitute medical advice. Treatment for SP-C deficiency-associated interstitial lung disease, including oxygen, medicines, nutrition, and transplant planning, should be individualized with your pulmonary care team.